ENGN
NASD enGene Therapeutics Inc.$1.95 ↓ -0.02 (-1.02%) Trading Down from the previous close of $1.97
- YTD change
- -78.41%
- vs 20-day SMA
- +2.83%
- vs 200-day SMA
- -62.54%
Price ranges
Price & Performance
-4.21 (-68.12%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 95.5% away from all-time highs of $43.00
- ENGN is down 78% since the beginning of the year
- ENGN is down 70% over the past 12 months
- ENGN is up 7% over the past 1 month
- 2% of all ENGN investors are betting against ENGN
ENGN reads not so good: price sits above one of the two key moving averages, the 12-month move is -69.5%.
- Previous minute
- -$0.08
- Last hour
- +$0.01
- Last 5 days
- -0.51%
- vs 8-day SMA
- -0.51%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
enGene Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. It is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. The company was founded by Anthony T. Cheung on April 24, 2023 and is headquartered in Saint-Laurent, Canada.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.